Equator Therapeutics vs IBM
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 biotech developing UCP1-activating thermogenesis drugs for obesity competing with GLP-1 agonists; seed-stage with proprietary HTS platform targeting brown fat calorie burning as next-generation anti-obesity mechanism.
About
Equator Therapeutics is a San Francisco-based early-stage biopharmaceutical company — backed by Y Combinator (W20) with seed funding from BioGenerator Ventures, Thoobik Holdings, Healthspan Capital, Endurance28, and Evolution VC Partners — developing first-in-class small molecule drugs that activate uncoupling protein 1 (UCP1) in brown and beige adipose tissue to increase metabolic rate and burn excess calories as heat, targeting obesity, metabolic syndrome, and related cardiometabolic diseases with a mechanism of action distinct from GLP-1 agonists (Ozempic, Wegovy) and traditional anti-obesity medications. Founded in 2019, Equator has developed a proprietary high-throughput drug discovery platform to identify selective UCP1 activators — compounds that safely activate the body's natural thermogenesis mechanism without the side effects (nausea, cardiovascular risk) that have limited previous metabolic drug programs.
Armonk NY hybrid cloud and enterprise AI (NYSE: IBM) at $62.8B revenue; $6B+ generative AI bookings, record $12.7B free cash flow 2024, DataStax acquisition for watsonx vector database competing with Microsoft Azure for enterprise AI.
About
International Business Machines Corporation (IBM) is an Armonk, New York-based global technology and consulting company — publicly traded on the New York Stock Exchange (NYSE: IBM) as an S&P 500 component — providing hybrid cloud infrastructure, artificial intelligence software, and enterprise IT consulting through approximately 270,300 employees in 170 countries with $62.8 billion in annual revenue. Founded on June 16, 1911, as Computing-Tabulating-Recording Company through a merger orchestrated by financier Charles Ranlett Flint, renamed IBM in 1924 under Thomas Watson Sr., IBM has undergone multiple strategic transformations over its 110+ year history: building the System/360 mainframe platform (1964), launching the IBM PC (1981), selling the PC division to Lenovo (2005, $1.75B), and completing the $34 billion Red Hat acquisition (2019) that repositioned IBM as a hybrid cloud platform company. CEO Arvind Krishna (appointed April 2020) has focused IBM's strategy on three areas: hybrid cloud (powered by Red Hat OpenShift, the enterprise Kubernetes platform), AI (the watsonx platform for enterprise AI model development and deployment), and enterprise consulting. Under Krishna, IBM recorded $12.7 billion in free cash flow in 2024 (a company record), surpassed $6 billion in generative AI bookings since June 2023, and saw the stock price double — trading at all-time highs through 2024-2025. IBM announced the DataStax acquisition in 2025 to deepen watsonx's data layer with AstraDB (vector database for AI applications), DataStax Enterprise (Apache Cassandra), and Langflow (low-code AI agent development).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.